Latest news with #GlycoMimetics
Business Wire
3 days ago
- Business
- Business Wire
GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) ('GlycoMimetics') today announced that its stockholders have approved the proposed merger (the 'Merger') with Crescent Biopharma, Inc. ('Crescent'), along with all proposals related to the Merger. The proposals were voted upon at GlycoMimetics' special meeting in lieu of the annual meeting of stockholders held on June 5, 2025 (the 'Special Meeting'), including a reverse stock split of GlycoMimetics' common stock to be effected at the discretion of the board of directors of GlycoMimetics (the 'Board') within the parameters approved by GlycoMimetics' stockholders. On June 5, 2025, following the Special Meeting, the Board approved a reverse stock split of GlycoMimetics' common stock at a ratio of 1-for-100. Following the anticipated closing of the Merger, the combined company's common stock is expected to begin trading on a post-reverse stock split basis on The Nasdaq Capital Market ('Nasdaq') on June 16, 2025, under the new name 'Crescent Biopharma, Inc.', ticker symbol 'CBIO', CUSIP number 38000Q201 and ISIN number US38000Q2012. The reverse stock split is expected to reduce the number of GlycoMimetics' outstanding common stock from approximately 64.5 million shares to approximately 0.6 million shares. The number of shares of GlycoMimetics' authorized common stock will not be affected by the reverse stock split. At the Special Meeting, GlycoMimetics' stockholders approved an increase in the number of shares of GlycoMimetics' authorized common stock from 150,000,000 shares to 175,000,000 shares in connection with the anticipated closing of the Merger. No fractional shares will be issued if, as a result of the reverse stock split, a stockholder would otherwise become entitled to a fractional share because the number of shares of GlycoMimetics common stock they hold before the reverse stock split is not evenly divisible by the split ratio. Instead, each stockholder will be entitled to receive a cash payment in lieu of such fractional share. The cash payment to be paid will be equal to the fraction of a share to which such stockholder would otherwise be entitled multiplied by the closing price per share as reported by The Nasdaq Stock Market LLC on June 12, 2025, the trading day prior to the date the charter amendment to effect the reverse stock split is expected to be filed with the Secretary of State of the State of Delaware (with such price proportionately adjusted to give effect to the reverse stock split). As a result of the reverse stock split, proportionate adjustments will be made to the exercise prices and number of shares of GlycoMimetics' common stock underlying GlycoMimetics' outstanding equity awards. There will be no change to the par value per share. Following the closing of the Merger, the combined company's total issued and outstanding common stock is expected to be approximately 14.8 million shares, or approximately 25.3 million shares on a fully-diluted basis. About GlycoMimetics, Inc. GlycoMimetics is a late clinical-stage biotechnology company that was previously discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases. The company's scientific approach was based on an understanding of the role that carbohydrates play in cell recognition. Its specialized chemistry platform can be used to discover small molecule drugs, known as glycomimetics, that alter carbohydrate-mediated recognition in diverse disease states, including cancers and inflammation. The company's goal was to develop transformative therapies for diseases with high unmet medical need. Learn more at About Crescent Biopharma, Inc. Crescent Biopharma, Inc. is a biotechnology company advancing novel precision-engineered molecules to advance care for patients with solid tumors. Crescent's pipeline of three programs harnesses validated biology to accelerate the path to market for potentially best-in-class therapeutics. Crescent's lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody, and it is also advancing CR-002 and CR-003, antibody drug conjugates with topoisomerase inhibitor payloads for undisclosed targets. For more information, visit and follow Crescent on LinkedIn. Forward-Looking Statements Certain statements in this press release, other than purely historical information, may constitute 'forward-looking statements' within the meaning of the federal securities laws, including for purposes of the 'safe harbor' provisions under the Private Securities Litigation Reform Act of 1995, concerning GlycoMimetics, Crescent, the proposed pre-closing financing and the proposed Merger between GlycoMimetics and Crescent (collectively, the 'Proposed Transactions') and other matters. These forward-looking statements include, but are not limited to: expectations related to anticipated timing of the closing of the Merger and satisfaction (or waiver) of closing conditions under the merger agreement; the combined company's listing on Nasdaq after the closing of the proposed Merger; the number of shares of GlycoMimetics common stock that may be outstanding as a result of the reverse stock split; and expectations regarding the ownership structure of the combined company. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words 'opportunity,' 'potential,' 'can,' 'goal,' 'strategy,' 'target,' 'anticipate,' 'achieve,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'plan,' 'possible,' 'project,' 'should,' 'will,' 'would' and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting GlycoMimetics, Crescent, the Proposed Transactions, or the reverse stock split will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of GlycoMimetics and Crescent) or other assumptions that may cause actual results, outcomes or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the conditions to the closing or consummation of the Proposed Transactions are not satisfied; the risk that the proposed pre-closing financing is not completed in a timely manner or at all; uncertainties as to the timing of the consummation of the Proposed Transactions and the ability of each of GlycoMimetics and Crescent to consummate the transactions contemplated by the Proposed Transactions; risks related to GlycoMimetics' continued listing on Nasdaq until closing of the Proposed Transactions and the combined company's ability to remain listed following the Proposed Transactions; risks related to GlycoMimetics' and Crescent's ability to correctly estimate their respective operating expenses and expenses associated with the Proposed Transactions, as applicable, as well as uncertainties regarding the impact any delay in the closing of any of the Proposed Transactions would have on the anticipated cash resources of the resulting combined company upon closing and other events and unanticipated spending and costs that could reduce the combined company's cash resources; the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the Proposed Transactions; the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the business combination between GlycoMimetics and Crescent; costs related to the Merger; as a result of adjustments to the exchange ratio, Crescent stockholders and GlycoMimetics stockholders could own more or less of the combined company than is currently anticipated; the outcome of any legal proceedings that may be instituted against GlycoMimetics, Crescent or any of their respective directors or officers related to the merger agreement or the transactions contemplated thereby; unexpected costs, charges or expenses resulting from the Proposed Transactions; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Proposed Transactions; and those uncertainties and factors more fully described in filings with the Securities and Exchange Commission (the 'SEC'), including reports filed on Form 10-K, 10-Q and 8-K, in other filings that GlycoMimetics makes and will make with the SEC in connection with the proposed Merger, including the proxy statement/prospectus, as well as discussions of potential risks, uncertainties, and other important factors included in other filings by GlycoMimetics from time to time, any risk factors related to GlycoMimetics or Crescent made available to you in connection with the Proposed Transactions, as well as risk factors associated with companies, such as Crescent, that operate in the biopharma industry. Should one or more of these risks or uncertainties materialize, or should any of GlycoMimetics' or Crescent's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Neither GlycoMimetics nor Crescent undertakes or accepts any duty to release publicly any updates or revisions to any forward-looking statements. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in GlycoMimetics or Crescent. No Offer or Solicitation This press release and the information contained herein is not intended to and does not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or in respect of the Proposed Transactions or (ii) an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities pursuant to the Proposed Transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except in accordance with the requirements of the Securities Act of 1933, as amended, or an exemption therefrom. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, no public offer will be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction. NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS PRESS RELEASE IS TRUTHFUL OR COMPLETE.
Yahoo
29-05-2025
- Business
- Yahoo
Crescent Biopharma to Present at the Jefferies Global Healthcare Conference
WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ('Crescent'), a private biotechnology company developing novel precision-engineered molecules targeting validated biology to advance care for patients with solid tumors, today announced that management is scheduled to present at the Jefferies Global Healthcare Conference in New York on Thursday, June 5, 2025, at 11:05 a.m. ET. A live webcast of the presentation will be available at and an archived replay will be accessible for 90 days following the event. In October 2024, Crescent entered into an acquisition agreement with GlycoMimetics, Inc. (Nasdaq: GLYC). Following closing, which is anticipated in the second quarter of 2025, the combined company will operate under the name Crescent Biopharma and advance Crescent's portfolio of precision-engineered molecules to improve outcomes for patients with solid Crescent Biopharma Crescent Biopharma, Inc. is a biotechnology company advancing novel precision-engineered molecules to advance care for patients with solid tumors. The Company's pipeline of three programs harnesses validated biology to accelerate the path to market for potentially best-in-class therapeutics. Crescent's lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody, and it is also advancing CR-002 and CR-003, antibody drug conjugates with topoisomerase inhibitor payloads for undisclosed targets. For more information, visit and follow us on LinkedIn. Contact Amy ReillyChief Communications in retrieving data Sign in to access your portfolio Error in retrieving data
Globe and Mail
07-03-2025
- Business
- Globe and Mail
Acute Myeloid Leukemia Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight's, 'Acute Myeloid Leukemia Pipeline Insight' report provides comprehensive insights about 110+ companies and 120+ pipeline drugs in Acute Myeloid Leukemia pipeline landscape. It covers the Acute Myeloid Leukemia pipeline drug profiles, including Acute Myeloid Leukemia clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Acute Myeloid Leukemia Treatment Landscape. Click here to read more @ Acute Myeloid Leukemia Pipeline Outlook Key Takeaways from the Acute Myeloid Leukemia Pipeline Report In March 2025, Janssen Research & Development, LLC conducted a study to determine the recommended Phase 2 dose(s) (RP2D[s]) of bleximenib in Phase 1 (Part 1 - Dose Escalation) and assess its safety and tolerability at RP2D in Phase 1 (Part 2 - Dose Expansion). The Phase 2 part of the study aims to evaluate the efficacy of bleximenib at the RP2D. In March 2025, Akeso initiated an open-label, Phase Ib/II study involving patients diagnosed with acute myeloid leukemia (AML) with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3. The study's objective is to evaluate the safety and efficacy of AK117 + azacitidine in AML patients. DelveInsight's Acute Myeloid Leukemia Pipeline analysis depicts a robust space with 110+ active players working to develop 120+ pipeline treatment therapies. The leading Acute Myeloid Leukemia Companies such as GlycoMimetics, BioSight, Merck Sharp & Dohme LLC, Kura Oncology, Senti Biosciences, Chimerix, Takeda, Apollo Therapeutics, Immune-Onc Therapeutics, AbbVie/Genentech, Altor BioScience Corporation, Merck & Co, Astex Pharmaceuticals, Karyopharm Therapeutics, Mesoblast, SELLAS Life Sciences Group, Molecular Partners, Kling Biotherapeutics, HitGen, Chordia Therapeutics, Inc, Cullinan Therapeutics Inc., Aptose Biosciences Inc., Celgene and others. Promising Acute Myeloid Leukemia Therapies such as OCV-501, SEL24/MEN1703, Venetoclax, Alvocidib, TL-895, KRT-232, XY0206, Azacitidine, Venetoclax, and others. Discover groundbreaking developments in Acute Myeloid Leukemia therapies! Gain in-depth knowledge of key Acute Myeloid Leukemia clinical trials, emerging drugs, and market opportunities @ Acute Myeloid Leukemia Clinical Trials Assessment Acute Myeloid Leukaemia Emerging Drugs Profile Uproleselan: GlycoMimetics GlycoMimetics is developing uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with Acute Myeloid Leukemia (AML) (AML) and potentially other hematologic cancers. Uproleselan is designed to bind to E-selectin and block the normal processes controlled by E-selectin. E-selectin is expressed on the surface of blood vessels, and its binding to myeloid cells confers a pro-survival effect via NF-kB signaling. Uproleselan is designed to provide a novel approach to disrupting established mechanisms of leukemic cell resistance. It is believed that by binding to E-selectin, uproleselan pushes AML cells out of their protective niche, blocks cellular communication signals that promote survival, and sensitizes cancer cells to the toxic effects of chemotherapy. Currently, the drug is in Phase III stage of its development for the treatment of Acute Myeloid Leukemia (AML). BST-236: BioSight Aspacytarabine (BST-236) is a novel proprietary anti-metabolite. It is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine, enabling delivery of high cytarabine doses to leukemia patients with lower systemic exposure to the free drug. Currently, the drug is in Phase II stage of its development for the treatment of Acute Myeloid Leukemia (AML). MK-0482: Merck Sharp & Dohme LLC MK-0482, a novel humanized IgG4 mAb targeting ILT3, is undergoing phase I evaluation ±pembrolizumab (pembro) in advanced solid tumors. MK-0482 ± pembro was generally well tolerated, and combination therapy provided modest antitumor activity in patients with heavily pretreated advanced solid tumors. The RP2D of MK-0482 + pembro is under further evaluation in tumor-specific cohorts. Currently, the drug is in Phase I stage of its development for the treatment of AML. Ziftomenib - Kura Oncology Ziftomenib is a novel, once-daily, oral investigational drug candidate targeting the menin-KMT2A/MLL protein-protein interaction for treatment of genetically defined AML patients with high unmet need. In preclinical models, ziftomenib inhibits the KMT2A/MLL protein complex and exhibits downstream effects on HOXA9/MEIS1 expression and potent anti-leukemic activity in genetically defined preclinical models of AML. Ziftomenib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of AML. Currently, the drug is in Phase I/II stage of its development for the treatment of AML. SENTI 202: Senti Biosciences SENTI-202 is a first in class Logic-gated CAR-NK product engineered with an OR and a NOT Logic Gate gene circuit approach to enhance therapeutic efficacy and safety, with additional arming via expression of calibrated release IL-15 (crIL-15). A dual targeting activating CAR (aCAR) that recognizes both CD33 and FLT3 tumor antigens improves the anti-tumor activity, ensuring the targeting of AML blasts and LSCs. Currently, the drug is in Preclinical stage of its development for the treatment of AML. The Acute Myeloid Leukemia pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Acute Myeloid Leukemia with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Myeloid Leukemia Treatment. Acute Myeloid Leukemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Acute Myeloid Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Myeloid Leukemia market Stay informed about the Acute Myeloid Leukemia pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Acute Myeloid Leukemia Unmet Needs Acute Myeloid Leukemia Companies GlycoMimetics, BioSight, Merck Sharp & Dohme LLC, Kura Oncology, Senti Biosciences, Chimerix, Takeda, Apollo Therapeutics, Immune-Onc Therapeutics, AbbVie/Genentech, Altor BioScience Corporation, Merck & Co, Astex Pharmaceuticals, Karyopharm Therapeutics, Mesoblast, SELLAS Life Sciences Group, Molecular Partners, Kling Biotherapeutics, HitGen, Chordia Therapeutics, Inc, Cullinan Therapeutics Inc., Aptose Biosciences Inc., Celgene and others. The Acute Myeloid Leukaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Acute Myeloid Leukaemia Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Transform your understanding of the Acute Myeloid Leukemia Pipeline! See the latest progress in drug development and clinical research @ Acute Myeloid Leukemia Market Drivers and Barriers, and Future Perspectives Scope of the Acute Myeloid Leukemia Pipeline Report Coverage- Global Acute Myeloid Leukemia Companies- GlycoMimetics, BioSight, Merck Sharp & Dohme LLC, Kura Oncology, Senti Biosciences, Chimerix, Takeda, Apollo Therapeutics, Immune-Onc Therapeutics, AbbVie/Genentech, Altor BioScience Corporation, Merck & Co, Astex Pharmaceuticals, Karyopharm Therapeutics, Mesoblast, SELLAS Life Sciences Group, Molecular Partners, Kling Biotherapeutics, HitGen, Chordia Therapeutics, Inc, Cullinan Therapeutics Inc., Aptose Biosciences Inc., Celgene and others. Acute Myeloid Leukemia Therapies- OCV-501, SEL24/MEN1703, Venetoclax, Alvocidib, TL-895, KRT-232, XY0206, Azacitidine, Venetoclax, and others. Acute Myeloid Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Acute Myeloid Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Stay Ahead in Oncology Research–Access the Full Acute Myeloid Leukemia Pipeline Analysis Today! @ Acute Myeloid Leukemia Drugs and Companies Table of Content Introduction Executive Summary Acute myeloid leukaemia: Overview Pipeline Therapeutics Therapeutic Assessment Acute myeloid leukaemia – DelveInsight's Analytical Perspective Late Stage Products (Phase III) Uproleselan: GlycoMimetics Drug profiles in the detailed report….. Mid Stage Products (Phase II) BST-236: BioSight Drug profiles in the detailed report….. Early Stage Products (Phase I) MK-0482: Merck Sharp & Dohme LLC Drug profiles in the detailed report….. Preclinical and Discovery Stage Products SENTI 202: Senti Biosciences Drug profiles in the detailed report….. Inactive Products Acute myeloid leukaemia Key Companies Acute myeloid leukaemia Key Products Acute myeloid leukaemia- Unmet Needs Acute myeloid leukaemia- Market Drivers and Barriers Acute myeloid leukaemia- Future Perspectives and Conclusion Acute myeloid leukaemia Analyst Views Acute myeloid leukaemia Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Yahoo
19-02-2025
- Business
- Yahoo
US Penny Stocks To Watch In February 2025
As the U.S. stock market navigates a mixed trading environment, with indices like the S&P 500 retreating slightly from record highs, investors are keeping an eye on smaller opportunities that might offer potential value. Penny stocks, though often associated with higher risk due to their smaller size and less-established nature, can still present intriguing investment possibilities when backed by strong financials and growth prospects. In light of current market conditions, we explore three penny stocks that stand out for their financial robustness and potential for long-term success. Name Share Price Market Cap Financial Health Rating BAB (OTCPK:BABB) $0.8625 $6.39M ★★★★★★ QuantaSing Group (NasdaqGM:QSG) $3.08 $127.27M ★★★★★★ ZTEST Electronics (OTCPK:ZTST.F) $0.2698 $9.16M ★★★★★★ Imperial Petroleum (NasdaqCM:IMPP) $2.79 $84.63M ★★★★★★ Permianville Royalty Trust (NYSE:PVL) $1.4389 $46.53M ★★★★★★ Golden Growers Cooperative (OTCPK:GGRO.U) $4.50 $67.38M ★★★★★★ Smith Micro Software (NasdaqCM:SMSI) $1.46 $24.65M ★★★★★☆ PHX Minerals (NYSE:PHX) $4.10 $154.8M ★★★★★☆ CBAK Energy Technology (NasdaqCM:CBAT) $0.89 $78.41M ★★★★★☆ Safe Bulkers (NYSE:SB) $3.69 $383.33M ★★★★☆☆ Click here to see the full list of 708 stocks from our US Penny Stocks screener. Let's explore several standout options from the results in the screener. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: GlycoMimetics, Inc. is a biotechnology company focused on discovering and developing therapies for cancers and inflammatory diseases in the United States, with a market cap of $18.71 million. Operations: GlycoMimetics, Inc. currently does not report any revenue segments. Market Cap: $18.71M GlycoMimetics, Inc., a biotechnology company with a market cap of US$18.71 million, is currently pre-revenue and faces significant challenges. The company reported a net loss of US$37.88 million for 2024, and its auditor expressed doubts about its ability to continue as a going concern. Recent executive departures coincide with plans for a merger with Crescent Biopharma, Inc., which may impact stability. GlycoMimetics has received an extension from Nasdaq to comply with listing requirements but risks delisting if it fails to meet the minimum bid price by June 2025. Despite being debt-free and having experienced leadership, financial uncertainties remain prominent factors for investors considering this penny stock. Jump into the full analysis health report here for a deeper understanding of GlycoMimetics. Evaluate GlycoMimetics' historical performance by accessing our past performance report. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: GSI Technology, Inc. designs, develops, and markets semiconductor memory solutions for various sectors including networking, industrial, medical, aerospace, and military across multiple countries with a market cap of $88.58 million. Operations: The company generates revenue primarily from the design, development, and sale of integrated circuits amounting to $19.79 million. Market Cap: $88.58M GSI Technology, Inc. operates in the semiconductor memory solutions sector with a market cap of US$88.58 million and recent quarterly sales of US$5.41 million, slightly up from the previous year. Despite being unprofitable with a net loss of US$4.03 million for the quarter, it remains debt-free and has seasoned management and board members with extensive tenure. The company's short-term assets exceed its liabilities, providing some financial stability despite having less than a year's cash runway based on current free cash flow trends. A potential contract award from the U.S. Army highlights its innovative Gemini-II technology's promising applications in military edge computing AI solutions. Get an in-depth perspective on GSI Technology's performance by reading our balance sheet health report here. Understand GSI Technology's track record by examining our performance history report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Butler National Corporation, with a market cap of $116.25 million, operates in the aerospace industry by designing, manufacturing, and servicing aerostructures and aircraft components globally. Operations: The company's revenue is primarily derived from its Gaming segment ($38.71 million), followed by Aircraft Modifications ($27.77 million), Special Mission Electronics ($13.81 million), and Aircraft Avionics ($2.49 million). Market Cap: $116.25M Butler National Corporation, with a market cap of US$116.25 million, shows promising financial metrics in the aerospace sector. Its short-term assets of US$37.8 million exceed both its short and long-term liabilities, indicating solid liquidity management. The company has achieved robust earnings growth of 79.4% over the past year, outpacing industry averages and reflecting high-quality earnings with a strong return on equity at 21.5%. Recent executive changes include Jeff Yowell's appointment as Executive Chairman to guide strategic growth alongside CEO Chris Reedy, following the termination of CFO Tad M. McMahon's employment earlier this year. Click here and access our complete financial health analysis report to understand the dynamics of Butler National. Learn about Butler National's historical performance here. Navigate through the entire inventory of 708 US Penny Stocks here. Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks. Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Jump on the AI train with fast growing tech companies forging a new era of innovation. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqCM:GLYC NasdaqGS:GSIT and OTCPK:BUKS. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
